Ferroptosis in cancer cells triggers PGE 2 production for tumour immune escape.

Ferroptosis, a form of cell death induced by overwhelming membrane lipid peroxidation, is a vulnerability of many cancers, including cancers resistant to current molecular and immune-based therapies 1-7 . Triggering of ferroptosis therefore provides an opportunity to achieve elimination of difficult-to-treat cancers 1-4,8,9 . Studies in mouse cancer models have demonstrated that anticancer immunity, mediated by dendritic cells (DCs) and CD8 + T cells, is essential for effective tumour eradicatio
Ferroptosis, a form of cell death induced by overwhelming membrane lipid peroxidation, is a vulnerability of many cancers, including cancers resistant to current molecular and immune-based therapies 1-7 . Triggering of ferroptosis therefore provides an opportunity to achieve elimination of difficult-to-treat cancers 1-4,8,9 . Studies in mouse cancer models have demonstrated that anticancer immunity, mediated by dendritic cells (DCs) and CD8 + T cells, is essential for effective tumour eradication by ferroptosis-inducing strategies 10-13 . However, ferroptotic cells limit this response 8-10,14 , resulting in immune escape and tumour growth through mechanisms that remain unclear. Here we demonstrate that ferroptotic cancer cells activate a molecular program resulting in aberrant production of prostaglandin E 2 (PGE 2 ), which limits the stimulation of anticancer CD8 + T cell responses by type 1 conventional DCs (cDC1s), thereby promoting immune escape. In ferroptotic cancer cells, lipid peroxidation-mediated membrane permeabilization enables Ca 2+ influx, which activates p38 MAPK signalling and thereby drives PGE 2 production. This signalling axis is uncoupled from cancer cell death and can be targeted to selectively interfere with immune-inhibitory PGE 2 production while preserving ferroptotic cancer cell elimination. In the context of cancer cell ferroptosis, ablation of PGE 2 production or disrupting PGE 2 signalling restores cDC1-mediated anticancer CD8 + T cell responses and leads to effective tumour elimination. Our findings identify a key mechanism that limits antitumour immunity and prevents tumour elimination upon ferroptosis induction in cancer cells, which could be exploited for cancer therapy.




